Asymmetric synthesis and evaluation of chiral lactam derivatives
Acknowledgments This work was supported by Grants of the
Korea Healthcare technology R&D Project, Ministry for Health,
Welfare & Family Affairs, Republic of Korea (A092006) and the
National Research Foundation of Korea (NRF) Grant funded by the
Korea government (MSIP) (No. 2007-0056817).
2007. Structure–activity relationship studies of a series of novel
d-lactam-based histone deacetylase inhibitors. Journal of Medic-
inal Chemistry 50: 2737–2741.
Longley, D.B., D.P. Harkin, and P.G. Johnston. 2003. 5-Fluorouracil:
Mechanisms of action and clinical strategies. Nature Reviews
Cancer 3: 330–338.
Lygo, B., and B.I. Andrews. 2004. Asymmetric phase-transfer
catalysis utilizing chiral quaternary ammonium salts: Asymmet-
ric alkylation of glycine imines. Accounts of Chemical Research
37: 518–525.
Maruoka, K., and T. Ooi. 2003. Enantioselective amino acid synthesis
by chiral phase-transfer catalysis. Chemical Reviews 103:
3013–3028.
References
Banik, B.K., F.F. Becker, and I. Banik. 2004. Synthesis of anticancer
beta-lactams: Mechanism of action. Bioorganic & Medicinal
Chemistry 12: 2523–2528.
Banik, B.K., and F.F. Becker. 2010. Selective anticancer activity of b-
lactams derived from polyaromatic compound. Molecular Med-
icine Reports 3: 315–316.
Choi, E., C. Lee, M. Cho, J.J. Seo, J.S. Yang, S.J. Oh, K. Lee, S.-K.
Park, H.M. H. M, H.J. Kwon, and G. Han. 2012. Property-based
optimization of hydroxamate-based c-lactam HDAC inhibitors
to improve their metabolic stability and pharmacokinetic
profiles. Journal of Medicinal Chemistry 55: 10766–10770.
Chow, L.Q.M., and S.G. Eckhardt. 2007. Sunitinib: From rational
design to clinical efficacy. JCO 25: 884–896.
Cohen, S.S., J.G. Flaks, H.D. Barner, M.R. Loeb, and J. Lichtenstein.
1958. The mode of action of 5-fluorouracil and its derivatives.
Proceedings of the National Academy of Sciences of the United
States of America 44: 1004–1012.
Cui, C.B., H. Kakeya, and H. Osada. 1996. Novel mammalian cell
cycle inhibitors, spirotryprostatins A and B, produced by
Aspergillus fumigatus, which inhibit mammalian cell cycle at
G2/M phase. Tetrahedron 52: 12651–12666.
Mehta, A., R. Jaouhari, T.J. Benson, and K.T. Douglas. 1992.
Improved efficiency and selectivity in peptide synthesis: Use of
triethylsilane as a carbocation scavenger in deprotection of t-
butyl esters and t-butoxycarbonyl-protected sites. Tetrahedron
Letters 33: 5441–5444.
Motzer, R.J., T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M.
Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S.T.
Kim, I. Chen, P.W. Bycott, C.M. Baum, and R.A. Figlin. 2007.
Sunitinib versus interferon alfa in metastatic renal-cell carci-
noma. New England Journal of Medicine 356: 115–124.
Natarajan, A., Y. Guo, F. Harbinski, Y.H. Fan, H. Chen, L. Luus, J.
Diercks, H. Aktas, M. Chorev, and J.A. Halperin. 2004. Novel
arylsulfoanilide-oxindole hybrid as an anticancer agent that
inhibits translation initiation. Journal of Medicinal Chemistry
47: 4979–4982.
ODonnell, M.J. 2004. The enantioselective synthesis of a-amino acids
by phase-transfer catalysis with achiral schiff base esters.
Accounts of Chemical Research 37: 506–571.
Demetri, G.D., A.T. van Oosterom, C.R. Garrett, M.E. Blackstein,
M.H. Shah, J. Verweij, G. McArthur, I.R. Judson, M.C.
Heinrich, J.A. Morgan, J. Desai, C.D. Fletcher, S. George,
C.L. Bello, X. Huang, C.M. Baum, and P.G. Casali. 2006.
Efficacy and safety of sunitinib in patients with advanced
gastrointestinal stromal tumour after failure of imatinib: A
randomised controlled trial. Lancet 368: 1329–1338.
Galliford, C.V., and K.A. Scheidt. 2007. Pyrrolidinyl-spirooxindole
natural products as inspirations for the development of potential
therapeutic agents. Angewandte Chemie International Edition
46: 8748–8758.
Hashimoto, T., and K. Maruoka. 2007. Recent development and
application of chiral phase-transfer catalysts. Chemical Reviews
107: 5656–5682.
Jemal, A., R. Siegel, E. Ward, Y.P. Hao, J.Q. Xu, T. Murray, and M.J.
Thun. 2008. Cancer statistics, 2008. CA: A Cancer Journal for
Clinicians 58: 71–96.
Jew, S.S., and H.G. Park. 2009. Cinchona-based phase-transfer
catalysts for asymmetric synthesis. Chemical Communications
14: 7090–7103.
Kamal, A., G. Ramakrishna, P. Raju, A.V. Rao, A. Viswanath, V.L.
Nayak, and S. Ramakrishna. 2011. Synthesis and anticancer
activity of oxindole derived imidazo[1,5-a]pyrazines. European
Journal of Medicinal Chemistry 46: 2427–2435.
Kim, H.M., D.-K. Ryu, Y. Choi, B.W. Park, K. Lee, S.B. Han, C.-W.
Lee, M.-R. Kang, J.S. Kang, S.K. Boovanahalli, S.-K. Park, J.W.
Han, T.-G. Chun, H.-Y. Lee, K.-Y. Nam, E.H. Choi, and G. Han.
Ooi, T., M. Kameda, and K. Maruoka. 2003. Design of N-spiro C2-
symmetric chiral quaternary ammonium bromides as novel
chiral phase-transfer catalysts: Synthesis and application to
practical asymmetric synthesis of a-amino acids. Journal of the
American Chemical Society 125: 5139–5151.
Park, Y., Y.J. Lee, S. Hong, M.-h Kim, M. Lee, T.-S. Kim, J.K. Lee,
S.-S. Jew, and H.-G. Park. 2011. Highly enantioselective phase-
transfer catalytic a-alkylation of a-tert-butoxycarbonyllactams:
Construction of b-quaternary chiral pyrrolidine and piperidine
systems. Advanced Synthesis and Catalysis 353: 3313–3318.
Park, Y., Y.J. Lee, S. Hong, M. Lee, and H.-g Park. 2012. Highly
enantioselective total synthesis of (?)-isonitramine. Organic
Letters 14: 852–854.
Ruf, S., G. Neudert, S. Gu¨rtler, R. Gru¨nert, P.J. Bednarski, and H.-H.
Otto. 2008. b-Lactam derivatives as potential anti-cancer
compounds. Monatshefte fuer Chemie 139: 847–857.
Silva, B.V., N.M. Ribeiro, M.D. Vargas, M. Lanznaster, J.W.
Carneiro, R. Krogh, A.D. Andricopulo, L.C. Dias, and A.C.
Pinto. 2010. Synthesis, electrochemical studies and anticancer
activity of ferrocenyl oxindoles. Dalton Transactions 39:
7338–7344.
Wissner, A., and C.V. Grudzinskas. 1978. Reaction of tert-butyldi-
methylsilyl esters with oxalyl chloride-dimethylformamide:
Preparation of carboxylic acid chlorides under neutral condi-
tions. Journal of Organic Chemistry 43: 3972–3974.
123